Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches

Cancer and Metastasis Reviews

Volumn 20, Issue 1-2, 2001, Pages 79-86

  Kerbel, Robert S ^a   Yu, Joanne ^a   Tran, Jennifer ^a   Man, Shan ^a   Viloria Petit, Alicia ^a   Klement, Giannoula ^a   Coomber, Brenda L ^b   Rak, Janusz ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Acquired drug resistance; Anti angiogenic drugs

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; INTERLEUKIN 12; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; SCATTER FACTOR; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOSTATIN; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RUGBY;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS;

EID: 0035692285     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013172910858     Document Type: Article

References (57)

1. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
2. Cancer: Looking outside the genome
3. The onset and extent of genomic instability in sporadic colorectal tumor progression
4. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas
5. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
6. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
7. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alpha-2a
8. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
9. Monoclonal antibodies targeting the VEGF receptor-2 (Flkl/KDR) as an anti-angiogenic therapeutic strategy
10. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
11. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
12. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects
13. Tumor angiogenesis: Past, present, and the near future
14. Mechanisms of angiogenesis and arteriogenesis
15. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
16. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
17. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
18. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas
19. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis
20. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
21. The challenge of pathway and environment-mediated drug resistance
22. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
23. Angiogenesis research: Guidelines for translation to clinical application
24. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
25. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
26. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
27. Role of endothelial cell survival and death signals in angiogenesis
28. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
29. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
30. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth
31. VEGF is required for growth and survival in neonatal mice
32. Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
33. Control of apoptosis during angiogenesis by survivin expression in endothelial cells
34. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting
35. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
36. Angiopoietin-1 regulates endothelial cell survival through the phosphafidylinositol 3′-Kinase/Akt signal transduction pathway
37. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway
38. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
39. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls
40. Heterogeneous vascular dependence of tumor cell populations
41. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy
42. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
43. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
44. Antiangiogenesis is produced by nontoxic doses of vinblastine
45. Redefining the target: Chemotherapeutics as antiangiogenics
46. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
47. Antitumor interaction of short-course endostatin and ionizing radiation
48. Combined effects of angiostatin and ionizing radiation in antitumour therapy
49. Antiangiogenic and antitumor activities of cyclooxygenase- 2 inhibitors
50. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
51. Thalidomide is an inhibitor of angiogenesis
52. Anfitumor activity of thalidomide in refractory multiple myeloma
53. V Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro
54. Low-molecular-weight heparin and cancer
55. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostafin and interleukin- 12
56. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
57. Combination oral anti-angiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits